Advertisement

Advertisement
Pancreatic Cancer

Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma

Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved long-term survival for patients with pancreatic ductal carcinoma, with a benefit of avoiding metastatic disease. However, there is a potential risk for postoperative morbidity that could interfere with systemic therapy. Nonoperative options are needed for patients unable to have surgery.

 

Solid Tumors

Early-Onset Breast, Colorectal, Endometrial, Pancreatic, and Kidney Cancers on the Rise

Recent studies have shown increasing rates of early-onset cancers, often defined as cancers occurring in people younger than age 50, especially colorectal, pancreatic, female breast, and uterine cancers, and younger birth cohorts seem to have a higher risk of some cancer types compared with older birth cohorts. A study by researchers at the National Cancer Institute (NCI) investigating cancer incidence in the United States between 2010 and 2019 has found that breast, colorectal, endometrial, pancreatic, and kidney cancers are becoming more common among individuals younger than age 50. Although the study did not find concomitant increases in mortality rates for most cancers, it showed that colorectal, uterine, and testicular cancer mortality rates also increased among younger adults. The findings may have implications for early-onset cancer prevention and screening efforts. The study by Shiels et al was published in Cancer Discovery.

Gynecologic Cancers

FDA Approves At-Home Self-Collection Device for Cervical Cancer Screening

Teal Health announced the U.S. Food and Drug Administration’s (FDA) approval of the Teal Wand™, an at-home vaginal sample self-collection device for cervical cancer screening in the United States. The Teal Wand is a prescription device that will soon be available at getteal.com for individuals aged 25 to 65 years at average risk for cervical cancer. The at-home screening includes both the Teal Wand collection kit and an end-to-end telehealth service providing virtual access to Teal medical providers who prescribe the kit, review the results from the lab, and support women throughout their at-home screening experience.


Advertisement
Solid Tumors
Colorectal Cancer
Lung Cancer
Symptom Management

In Case You Missed It: Additional Abstracts of Interest From AACR

Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers and clinicians.

Issues in Oncology

Patterns in Oncology Drug Use After Accelerated Approval Is Withdrawn

The accelerated approval program of the U.S. Food and Drug Administration (FDA) allows certain medications to be marketed if they are indicated for serious disease and there has been preliminary evidence of the drug’s efficacy. Pharmaceutical companies must then conduct postapproval trials to confirm the medication’s clinical benefit. If the postapproval trial fails, the indication should be removed from the product’s label. Some of these medications can remain available if they have other approved indications and may continue to be prescribed off-label for the withdrawn indication.

Advertisement
Advertisement




More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Multiple Myeloma

How Could So Many Physicians Have Failed Me?

Oya Gilbert The first sign that something was terribly wrong was in 2015, when I began to feel so fatigued that it was difficult to get out of bed even after 8 to 10 hours of sleep. I’ve been full of energy my whole life and couldn’t understand why I was so tired all the time. Then I began to ...

Advertisement

Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer

In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and fulvestrant showed activity in heavily pretreated patients with hormone receptor (HR)-positive,...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Rakesh K. Jain, PhD, FAACR, Honored With 2025 AACR Award for Lifetime Achievement in Cancer Research

Rakesh K. Jain, PhD, FAACR The 2025 AACR Award for Lifetime Achievement in Cancer Research was presented to Rakesh K. Jain, PhD, FAACR, during the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago. This award honors individuals who have made significant...

Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD

Thomas B. Tomasi, Jr, MD, PhD Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s...

Breast Parenchymal Phenotypes and Risk of Breast Cancer

Six parenchymal phenotypes were established that may be associated with a higher risk of developing breast cancer. Studies of these phenotypes identified by radiomics on mammograms demonstrated that these patterns were associated with an increased risk of invasive breast cancer, according to...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Keith T. Flaherty, MD, FAACR, Elected as AACR President-Elect for 2025–2026

Keith T. Flaherty, MD, FAACR The members of the American Association for Cancer Research (AACR) have elected Keith T. Flaherty, MD, FAACR, as the AACR President-Elect for 2025–2026. He will assume the Presidency in April 2026 at the AACR Annual Meeting in San Diego. Dr. Flaherty is Director...

Advertisement

Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in colorectal cancer, offering dynamic insight into disease burden and recurrence risk. However, questions remain about its clinical utility and optimal application, as well as its equitable access across practice settings. At the...

ASCO Post X Feed
Social Media Hub by Everwall